Business Wire

WISDOM

14.10.2021 18:02:04 CEST | Business Wire | Press release

Share
Clubhouse Meets Masterclass! Wisdom App Launches World’s Largest Mentorship Platform via Social Audio

Wisdom – the social audio app built to democratise mentorship – is now live in the UK, the US, Australia, and Canada. Founded by Dayo Akinrinade, the Wisdom app is an inclusive space where diverse people come together to have conversations that matter.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005070/en/

On a mission to become the next big social audio community, Wisdom taps into the intimacy and authenticity provided by the emerging medium. Drop-in social audio is transforming social networking because it takes interactions and conversations back to their roots. As the oldest medium, and one that is the most “human” of all societal interactions, audio is the antithesis of the heavily filtered nature of today’s visual-led apps and one which helps amplify voices of all groups and communities.

Wisdom is the latest app to launch in the white hot social audio market. Unlike other social audio applications, like Clubhouse, Wisdom is designed from the ground up to promote conversations that matter: conversations of substance on a topic of importance. Members can chat live with experts in dozens of topics from parenting, fitness, and dating to startups, mental health, and beauty. They can listen live or playback the recordings in their own time.

In Wisdom, when a mentor starts a talk, listeners can queue up to ask questions. A timer keeps the conversation moving so no one guest can monopolise the conversation; making sure all voices are heard. Inspired by Tiktok, Wisdom leverages an algorithm-first design that quickly learns what members like to listen to. Talk recommendations are made by a deep-learning neural network.

Dayo Akinrinade, founder and CEO of Wisdom, said : “I founded Wisdom to democratise access to mentorship. During my time at OneTech , London's largest diversity in startups programme, I noticed that diverse individuals from underrepresented groups lack access to mentoring. I also personally experienced how impossible it is to use platforms like LinkedIn for mentoring. The inboxes of experts are inundated with “pick your brain” requests which end up ignored unless the request is via a warm introduction, which is itself a crystallisation of systemic inequality.”

A global platform for mentorship

Connecting with others in a meaningful way has been proven to make people happier, with deep conversations with strangers more enjoyable than small talk. Wisdom will cultivate this, with thousands of people already signed up as mentors, making it the largest platform for mentorship in the world. These experts will be able to use Wisdom to share their knowledge, interact directly with their audience and give back while getting on the ground floor of the next big social audio community.

Though the platform will be free to members, as part of its mission to democratise mentorship, Wisdom will also empower its mentors through monetisation tools so they can grow their own businesses. Monetisation features will be added to Wisdom later this year.

Akinrinade added: “Consider that Masterclass has no more than hundreds of experts on its platform and does not allow deep interactions and is not free. With Wisdom, we are building something very different. Ultimately what we are building with Wisdom is a new social graph … the Mentor Graph. This is not a messy ‘talk graph’ of anyone on any topic but a social graph of the people who can help jumpstart a career, or change a life for the better. People today hunger for conversations that matter. We believe Wisdom is the platform where these conversations can live.”

The Wisdom app is available for download today for iPhone. Android is coming soon.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye